Cardiotoxicity in low-to-moderate cardiovascular risk patients undergoing anti-HER2 therapy: A prospective CMR study. Radiol Oncol. 2025;59(4):510-521. Accessed September 30, 2026. https://www.radioloncol.com/index.php/ro/article/view/4626